重庆医科大学学报
重慶醫科大學學報
중경의과대학학보
UNIVERSITATIS SCIENTIAE MEDICINAE CHONGQING
2009年
12期
1666-1669
,共4页
全反式维甲酸%卵巢癌%增殖%侵袭
全反式維甲痠%卵巢癌%增殖%侵襲
전반식유갑산%란소암%증식%침습
All-trans retinoic acid%Ovarian carcinoma%Proliferation%Invasion
目的:观察全反式维甲酸(All-trans retinoic acid,ATRA)对体外培养人卵巢癌细胞株HO8910增殖、侵袭能力的影响,为ATRA应用于卵巢癌的临床治疗提供实验依据.方法:选用人卵巢癌细胞株HO8910进行体外培养,以不同浓度的ATRA处理HO8910细胞,四甲基偶氮唑蓝(MTT)比色法检测细胞增殖抑制情况,倒置显微镜进行形态学观察,Transwell小室体外侵袭实验检测细胞侵袭能力.结果:(1)ATRA浓度为10~(-7)～10~(-5)mol/L时,均明显抑制HO8910细胞的增殖(P<0.05),并具有时间-剂量依赖性.24、48、72 h ATRA抑制HO8910细胞增殖的IC_(50)值分别为2.331×10~(-5)、0.998×10~(-6)、0.891×10~(-7)mol/L.(2)倒置显微镜可观察到经10~(-6)mol/LATRA处理的HO8910细胞部分发生形态学的良性分化.(3)体外侵袭实验显示经10~(-6)mol/L ATRA处理的HO8910细胞,穿膜细胞数目明显减少(P<0.05).结论:ATRA能明显抑制人卵巢癌细胞株HO8910的增殖、侵袭能力,有望为ATRA应用于卵巢癌的临床治疗提供新的有效的途径.
目的:觀察全反式維甲痠(All-trans retinoic acid,ATRA)對體外培養人卵巢癌細胞株HO8910增殖、侵襲能力的影響,為ATRA應用于卵巢癌的臨床治療提供實驗依據.方法:選用人卵巢癌細胞株HO8910進行體外培養,以不同濃度的ATRA處理HO8910細胞,四甲基偶氮唑藍(MTT)比色法檢測細胞增殖抑製情況,倒置顯微鏡進行形態學觀察,Transwell小室體外侵襲實驗檢測細胞侵襲能力.結果:(1)ATRA濃度為10~(-7)～10~(-5)mol/L時,均明顯抑製HO8910細胞的增殖(P<0.05),併具有時間-劑量依賴性.24、48、72 h ATRA抑製HO8910細胞增殖的IC_(50)值分彆為2.331×10~(-5)、0.998×10~(-6)、0.891×10~(-7)mol/L.(2)倒置顯微鏡可觀察到經10~(-6)mol/LATRA處理的HO8910細胞部分髮生形態學的良性分化.(3)體外侵襲實驗顯示經10~(-6)mol/L ATRA處理的HO8910細胞,穿膜細胞數目明顯減少(P<0.05).結論:ATRA能明顯抑製人卵巢癌細胞株HO8910的增殖、侵襲能力,有望為ATRA應用于卵巢癌的臨床治療提供新的有效的途徑.
목적:관찰전반식유갑산(All-trans retinoic acid,ATRA)대체외배양인란소암세포주HO8910증식、침습능력적영향,위ATRA응용우란소암적림상치료제공실험의거.방법:선용인란소암세포주HO8910진행체외배양,이불동농도적ATRA처리HO8910세포,사갑기우담서람(MTT)비색법검측세포증식억제정황,도치현미경진행형태학관찰,Transwell소실체외침습실험검측세포침습능력.결과:(1)ATRA농도위10~(-7)～10~(-5)mol/L시,균명현억제HO8910세포적증식(P<0.05),병구유시간-제량의뢰성.24、48、72 h ATRA억제HO8910세포증식적IC_(50)치분별위2.331×10~(-5)、0.998×10~(-6)、0.891×10~(-7)mol/L.(2)도치현미경가관찰도경10~(-6)mol/LATRA처리적HO8910세포부분발생형태학적량성분화.(3)체외침습실험현시경10~(-6)mol/L ATRA처리적HO8910세포,천막세포수목명현감소(P<0.05).결론:ATRA능명현억제인란소암세포주HO8910적증식、침습능력,유망위ATRA응용우란소암적림상치료제공신적유효적도경.
Objective:To investigate the effects of all-trans retinoie acid on the human ovarian cancer cell line HO8910.Methods:The human ovarian cancer cell line HO8910 cultured in vitro were treated with various concentrations of all-trans retinoic acid.The cell proliferation inhibition was detected by MTT assay;The morphologic changes of cell differentiation were observed under inverted microscope;The invasion capability was evaluated by transwell chambers.Resets:1.ATRA of 10~(-7)～10~(-5)mol/L inhibited the proliferation of HO8910 cell significantly in a dose-dependent and time-dependent manner(P<0.05)and its IC_(50) were 2.331 × 10~(-5)mol/L、0.998×10~(-6) mol/L、0.891×10~(-7)mol/L at 24 hours、48 hours and 72 hours,separately.2.Treated by 10~(-6) mol/L ATRA,HO8910 cells showed striking morphological characteristics of differentiation under microscope.3.The number of invasive cells decreased significantly after treated by 10~(-6) mol/L ATRA(P<0.05).Conclusion:ATRA can both inhibit the proliferation and invasion of human ovarian cancer cell line HO8910.Which expect to provide an effective and novel approach for clinical treatment of human ovarian cancer.
